WeissLaw LLP, a national class action, shareholder rights law firm with offices in New York, Los Angeles, and Atlanta, announces an investigation of Acadia Pharmaceuticals, Inc. (the “Company” or “ACAD”) (NASDAQ: ACAD), its Board of Directors, and certain Company officers, for among other things, possible breaches of fiduciary duty and violations of Federal and State laws.
August 24, 2018
· 1 min read